perfluorooctylbromide and CO2 drug combination
Also Known As:
PFOB and CO2 drug combination; S-1226; S1226; perfluorooctylbromide and carbon dioxide drug combination; perfluorooctylbromide-CO2 drug; perfluorooctylbromide-carbon dioxide; perfluorooctylbromide-carbon dioxide drug combination
Networked: 2
relevant articles (2 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Chiu, Andrea:
2 articles
(06/2018 - 01/2016)
|
| 2. | Dennis, John H:
2 articles
(06/2018 - 01/2016)
|
| 3. | El Mays, Tamer Y:
2 articles
(06/2018 - 01/2016)
|
| 4. | Fadayomi, Morenike:
2 articles
(06/2018 - 01/2016)
|
| 5. | Green, Francis H Y:
2 articles
(06/2018 - 01/2016)
|
| 6. | Lalli, Gurkeet:
2 articles
(06/2018 - 01/2016)
|
| 7. | Leigh, Richard:
2 articles
(06/2018 - 01/2016)
|
| 8. | Nelson, David Evan:
2 articles
(06/2018 - 01/2016)
|
| 9. | Pieron, Cora A:
2 articles
(06/2018 - 01/2016)
|
| 10. | Shrestha, Grishma:
2 articles
(06/2018 - 01/2016)
|
Related Diseases
| 1. | Asthma (Bronchial Asthma)
01/01/2016
- " S-1226 has a low toxicity profile and was effective in treating bronchoconstriction in animal models of asthma. " 01/01/2016
- " S-1226 is a novel drug being developed for the treatment of acute asthma exacerbations. " 06/18/2018
- " S1226 was safe, tolerated well, and provided bronchodilation and improved blood oxygenation in subjects with mild atopic asthma following allergen-induced bronchoconstriction. " 06/18/2018
- " This was a phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover single-dose clinical trial to evaluate the safety, tolerability, and efficacy of S1226 (8% CO2) administered by nebulization following an allergen-induced early asthmatic response in 12 subjects with mild, allergic asthma. " 06/18/2018
- " This study evaluates a novel bronchodilator, S1226, for its efficacy in reversing allergen-induced bronchoconstriction in subjects with mild, allergic asthma. "
|
|
Related Drugs and Biologics